Search

Science could lead to a new type of opioid drug that blocks pain but has a lower potential for addiction or abuse.

… Thursday, January 4, 2018 Summary A multicenter team of researchers is using structural and chemical biology to determine ways to block pain with opioids that have a lower potential for addiction or abuse. The United States is in the midst of an opioid epidemic. According to the Centers for Disease Control

Follow these guidelines for holding difficult yet important end-of-life conversations.

… Thursday, June 20, 2019 Summary End-of-life conversations are never easy. Your care team at Memorial Sloan Kettering is here to listen to your wishes and validate your feelings. Not many people are comfortable talking about death. But sometimes, the only way to get more comfortable with something is

Each summer, four summer students are named Rubin and Sarah Shaps Scholars. They are selected on the basis of their outstanding undergraduate credentials and their performance in our Summer Undergraduate Research Program.

… Tuesday, August 30, 2011 Each summer, four summer students are named Rubin and Sarah Shaps Scholars. They are selected on the basis of their outstanding undergraduate credentials and their performance in our Summer Undergraduate Research Program. Daniel Holohan, a sophomore majoring in Biochemistry/Molecular

Learn how FDA approval of a new multiple myeloma drug will brighten the outlook for people with resistant forms of the disease.

… Tuesday, October 25, 2022 People with multiple myeloma , a rare blood cancer, got good news today when the FDA approved a new drug for resistant forms of the disease. The drug, teclistamab, has been proven effective in treating people with multiple myeloma for whom previous therapies have not worked.

Learn how MSK doctors are exploring the use of less radiation in neuroblastoma treatment so children can avoid side effects.

… Thursday, December 21, 2023 Summary Treatment for high-risk forms of neuroblastoma is effective but can cause serious complications. MSK researchers are investigating using a lower radiation dose to treat this cancer, which occurs in young children. Early results have shown that a reduced radiation dose

Learn about the 21st Century Cures Act, which set out to improve the way providers share information to coordinate the care of their patients and to improve patients’ access to their own medical information.

… Friday, January 31, 2025 Transparency with patients and caregivers is a fundamental part of the mission of Memorial Sloan Kettering Cancer Center (MKS).  We have always believed that you should be empowered with the information you need to understand and manage your care.  The 21st Century Cures Act

MSK gynecologic surgeon Carol Brown, MD, participated in a Fireside Chat on Health Equity for the Becker’s Healthcare Virtual Oncology Forum.

… Wednesday, September 8, 2021 Carol Brown, MD , Senior Vice President, Office of the Hospital President, participated in a Fireside Chat on Health Equity for the Becker’s Healthcare Virtual Oncology Forum on July 26, 2021. During the discussion, Dr. Brown spoke in-depth about addressing cancer health

These souped-up versions may help overcome some limitations of existing CAR T cells.

… Thursday, December 30, 2021 Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient’s own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood cancers. Now, scientists at Memorial

Researchers led by scientists at Memorial Sloan Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of PTEN function. The findings from two related studies are published in the January 12 issue of Cell.

… Friday, January 12, 2007 PTEN is one of the most commonly mutated tumor suppressor genes. It is an antagonist for many cellular growth, proliferation and survival processes. When mutated or deleted, it causes cancers of the prostate, breast, colon, and brain. Researchers led by scientists at Memorial

Memorial Sloan Kettering hosted its 24th annual “Thrivers” celebration to honor the patients, staff, and caregivers of the MSK Bone Marrow Transplantation (BMT) Service.

… Friday, September 13, 2019 It was a night of long hugs, standing ovations, well-earned tears, and “can you believe it?” stories, as Memorial Sloan Kettering hosted a lavish party to honor the patients, staff, and caregivers of MSK’s renowned Bone Marrow Transplant (BMT) Service . The event marked MSK